Serum apolipoprotein C‐III in high‐density lipoprotein: a key diabetogenic risk factor in Turks

Aims  We studied determinants of serum apolipoprotein C‐III (apoC‐III) and whether levels of apoC‐III or its fractions predict metabolic syndrome (MetS), Type 2 diabetes and coronary heart disease (CHD).

[1]  G. Can,et al.  The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. , 2010, International journal of cardiology.

[2]  G. Can,et al.  Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks. , 2009, Metabolism: clinical and experimental.

[3]  Masayuki Yoshida,et al.  Apolipoprotein CIII links dyslipidemia with atherosclerosis. , 2009, Journal of atherosclerosis and thrombosis.

[4]  H. Hashimoto,et al.  Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[5]  F. Sacks,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients , 2008, Diabetes & vascular disease research.

[6]  S. Dodani.  Excess coronary artery disease risk in South Asian immigrants: Can dysfunctional high-density lipoprotein explain increased risk? , 2008, Vascular health and risk management.

[7]  S. Yusuf,et al.  Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample , 2007, BMC Medical Genetics.

[8]  G. Can,et al.  Prospective epidemiologic evidence of a "protective" effect of smoking on metabolic syndrome and diabetes among Turkish women--without associated overall health benefit. , 2007, Atherosclerosis.

[9]  G. Can,et al.  Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. , 2007, Atherosclerosis.

[10]  G. Can,et al.  Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation , 2007, International Journal of Obesity.

[11]  Nancy Dekki,et al.  Apolipoprotein CIII promotes Ca2+-dependent β cell death in type 1 diabetes , 2004 .

[12]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[13]  E. Trabetti,et al.  Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease Published, JLR Papers in Press, October 16, 2003. DOI 10.1194/jlr.M300253-JLR200 , 2003, Journal of Lipid Research.

[14]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[15]  F. Sacks,et al.  LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic Patients , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[16]  G. Assmann,et al.  Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. , 2003, Atherosclerosis.

[17]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[18]  A. Onat,et al.  Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation. , 2002, Atherosclerosis.

[19]  A. Sniderman,et al.  Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.

[20]  A. Onat.  Risk factors and cardiovascular disease in Turkey. , 2001, Atherosclerosis.

[21]  M. Pfeffer,et al.  VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial , 2000, Circulation.

[22]  M. Tremblay,et al.  Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. , 2000, Journal of lipid research.

[23]  G. Thompson.  Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. , 1998, European heart journal.

[24]  D. Arveiler,et al.  Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde. , 1996, Journal of lipid research.

[25]  J. Auwerx,et al.  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. , 1995, The Journal of clinical investigation.

[26]  D H Blankenhorn,et al.  Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. , 1990, Circulation.

[27]  C. S. Wang,et al.  Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. , 1985, The Journal of clinical investigation.

[28]  R. Krauss,et al.  Further Observations on the Activation and Inhibition of Lipoprotein Lipase by Apolipoproteins , 1973, Circulation research.

[29]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[30]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[31]  M. Tremblay,et al.  Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. , 2001, Metabolism: clinical and experimental.